Total
0
Shares
Holista Colltech (ASX:HCT) - Managing Director, Dr Rajen Manicka - The Market Herald
Managing Director, Dr Rajen Manicka
Sourced: The Edge Markets
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Holista CollTech (HCT) shares have risen after launching its Bioesque disinfectant, which is listed on the Environmental Protection Agency's 'List N'
  • Bioesque is a natural disinfectant that kills COVID-19 in buildings
  • Products that are listed on List N have met the criteria for use against SARS-CoV-2, the virus that causes COVID-19
  • Bioesque will be used in Global Infection Control Consultants' M3 system, which will be integrated into buildings ventilation
  • On the market today, Holista is up 16.7 per cent and trading at 7.7 cents per share

Holista CollTech (HCT) shares have risen after launching its 'List N' disinfectant, Bioesque, to kill COVID-19 in buildings.

Products that are listed on the Environmental Protection Agency’s (EPA’s) List N have met the criteria for use against SARS-CoV-2, the virus that causes COVID-19.

Laboratoire M2 will supply Bioesque for use in the M3 system, while HCT's other disinfectant, Path Away, is in the process of being registered on List N.

Like Path Away, Bioesque is a botanical 100 per cent natural disinfectant.

What is the M3 system?

The M3 system can be used as a flogging (mist or fog) solution and can be integrated with a building's heating, ventilation and air-conditioning (HVAC) system.

The M3 system was created by Holista’s joint-venture partner, Global Infection Control Consultants (GICC).

Disinfectants like Bioesque will be sprayed across the buildings to kill germs. However, the disinfectants will be made only from natural ingredients, which are not harmful to humans.

"It is critical that we are able to offer a List N solution now as the market opportunity for the M3 system has never been greater,” GICC President Dr Arthur V. Martin said.

"Even as a COVID-19 vaccine is being rolled out today, there will still be strong
demand for solutions like M3 in the long-term given the considerable time it takes
for a vaccine to be distributed to the population-at-large, and the increased focus on controlling all types of viruses in the post-COVID world," he added.

Currently, Path Away and Bioesque are the only two disinfectants that have been approved by GICC for use in the M3 System.

"It is exciting to be able to offer a List N certified solution today while GICC and
Holista are in the process of additionally getting Path-Away on the EPA’s List N," Holista CEO Dr Rajen Manicka said.

"Having the flexibility to offer Bioesque with the M3 system will allow us to
immediately offer a fully approved solution at a time of real need," he added.

Currently, the average number of COVID-19 cases in the U.S. is close to 200,000 a day, and one American dies every 30 seconds from the disease. U.S. health officials are expecting it to get worse over Christmas.

On the market today, Holista is up 16.7 per cent and is trading for 7.7 cents per share at 12:58 pm AEDT.

HCT by the numbers
More From The Market Herald
Genetic Technology’s (ASX:GTG) break-through breast cancer technology to go on sale in 2020

" Genetic Technologies (ASX:GTG) signs agreement to distribute COVID test in U.S.

Genetic Technologies (GTG) has signed a three-year agreement with Infinity BiologiX to produce and distribute its COVID-19 risk test in the U.S.
Pacific Smiles (ASX:PSQ) raises $15M for dental centre rollout

" Pacific Smiles (ASX:PSQ) raises $15M for dental centre rollout

Dental centre operator Pacific Smiles (PSQ) has successfully completed its $15 million placement.
MGC Pharmaceuticals (ASX:MXC) - Co Founder and Managing Director, Roby Zomer - The Market Herald

" MGC Pharmaceuticals (ASX:MXC) receives boosted ArtemiC order from SPC

MGC Pharmaceuticals (MXC) has received a significantly increased order from Swiss PharmaCan (SPC) for its ArtemiC Rescue product line.
Orthocell (ASX:OCC) - Managing Director, Paul Anderson - The Market Herald

" Orthocell (ASX:OCC) granted inclusion on Australian Prostheses List

Regenerative medicine company Orthocell (OCC) has been granted inclusion on the Australian Prostheses List.